An observational study in Multiple Sclerosis, sponsored by Clinique Neuro-Outaouais. Completed at 1 site in Canada. Open to participants aged 18 Years to 58 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-06.
Sponsored by Clinique Neuro-Outaouais · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 257 studies in Multiple Sclerosis with a site in Canada — 25 open to participants now, 43 under way, 12 of them phase 3. Multiple Sclerosis · Canada.
Among the 257 studies in Multiple Sclerosis with a site in Canada, this one is the 38th largest by enrollment of the 42 observational ones that give a count, is one of 10 that started in 2016, is one of 42 observational ones, and was the 152nd registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →25 of the 257 studies in Multiple Sclerosis with a site in Canada are open now. Recruiting first, the newest first:
Kite, A Gilead Company · Sites in Canada, United States, Australia
Ages 18–75
University Health Network, Toronto · Sites in Canada
Ages 18–65
AstraZeneca · Sites in Canada, United States, Australia and 2 more countries
Ages 18–60
University of Calgary · Sites in Canada
Ages 26–59
Novartis Pharmaceuticals · Sites in Canada, United States, Argentina and 33 more countries
Ages 18–65
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 58 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
257 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 60 · Phase 3 85 · Phase 4 13
First in 2001; this study’s year is marked. 10 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Median enrollment 177 across the 215 interventional studies, 172 across the 42 observational. Of the 200 that completed or were terminated, 97 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 257 have an industry lead sponsor. The 10 most frequent:
Clinique Neuro-Outaouais is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Clinique Neuro-Outaouais has 6 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
12 of the studies in Multiple Sclerosis with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT06415552Robert SimpsonImplementation of Online Mindfulness-Based Stress Reduction Tailored for People with Multiple Sclerosis | 2026-12-31 |
| NCT04121468The Hospital for Sick ChildrenA Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis | 2027-03 |
| NCT05090371Novartis PharmaceuticalsA Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation | 2027-04-13 |
| NCT06782490CelgeneA Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | 2027-05-26 |
Add all 12 to your calendar (.ics) → With an account.
Among the 257 studies in Multiple Sclerosis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study Objectives and Endpoints:
Objective:
The primary objective of the study is to evaluate the feasibility and test-retest reliability of MEP's and (SSEP's) in a multicenter clinical trial in healthy subjects and subjects with MS.
Endpoints:
The primary reliability endpoint will be the intraclass correlation coefficient (ICC) of the following evoked potential parameters
The establishment of a biomarker(s) that can predict a clinical response to therapy over the course of a 1-2 year clinical trial is critical for the expeditious development of treatments for Multiple Sclerosis (MS). Identification of this biomarker would enable shorter and smaller clinical trials resulting in the faster development of much needed treatments for MS, specifically neuro-reparative therapies. The etiology of disease progression is conduction block, demyelination and axonal degeneration. Evoked potentials provide a direct assessment of the underlying etiologies of disease progression in MS. They are a functional assessment of multiple pathways, including visual, motor and sensory, evaluating the integrity of myelin and axons.
The variability of motor evoked potentials (MEP) measures has limited multimodal evoked potential (mmEP) use in international, multicenter clinical trials. MEP evaluation does significantly contribute to the predictive value of mmEP's. Recent advances in technology and establishment of standardized protocols for MEP reduces the variability associated with this procedure. The objective of this study is to evaluate the reliability and feasibility of MEP and SSEP in an international, multicenter trial so that mmEP can be further evaluated as a biomarker for disease progression. The rationale for this study is to explore the feasibility and reliability of MEP's and somatosensory evoked potentials (SSEP's) in a multicenter clinical trial for potential use as a biomarker that can predict clinical progression/improvement in international clinical trials evaluating remyelinating therapies.
Study Objectives and Endpoints:
Objective:
The primary objective of the study is to evaluate the feasibility and test-retest reliability of MEP's and (SSEP's) in a multicenter clinical trial in healthy subjects and subjects with MS.
Endpoints:
The primary reliability endpoint will be the intraclass correlation coefficient (ICC) of the following evoked potential parameters
Motor Evoked parameters that will be measured:
Study Design:
This multinational, multicenter study will be conducted in healthy adult volunteers and MS patients to establish the feasibility and reliability of mmEP's. A total of 40 subjects, 10 (5 healthy and 5 MS) from each of the 4 sites will be enrolled.
The study will consist of two visits, 1-30 days apart, during which subjects will be screened to confirm eligibility and will complete all specified study assessments.
Study Locations:
Canada, Germany, Switzerland and Italy, with 1 site in each country.
Number of Planned Subjects:
A minimum of 40 subjects are planned for this study. Subjects who withdraw from the study prior to completion of the second visit may be replaced at the discretion of the investigator.
Study Population:
This study will be conducted in subjects 25 to 58 years of age, inclusive, who are either healthy volunteers (HV) or have been diagnosed with clinically definite MS who have a detectable lesion by MEP or SSEP.
Study Groups:
Two groups, healthy volunteers and clinically definite MS will be included.
Duration of Study Participation:
Study duration for each subject will be two visits, the second visit schedule >24 hours-30 days from the first visit
Criteria for Evaluation:
Key Study Assessments:
Electrophysiological. MEP's and SSEPs will be measured in both upper and lower limbs bilaterally. All studies will be read locally and reviewed by a blinded reader at another center. The ICC of every measured evoked potential parameter will be determined on both the central and local reads.
Healthy volunteers and MS patients aged 18 to 58 that have no other neurological comorbities that could affect evoked potential responses
Inclusion Criteria:
To be eligible to participate in this study, candidates must meet the following eligibility criteria at Screening, or at the time point specified in the individual eligibility criterion listed (HV cohort):
Inclusion Criteria (MS Cohort)
To be eligible to be included in this cohort, candidates must meet the following additional eligibility criteria at Screening:
Exclusion Criteria:
Candidates will be excluded from study entry if any of the following exclusion criteria exist at screening or at any time during the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
healthy volunteers, 18 to 58 years old, with no neurological disease that could affect evoked potential responses Intervention: multimodal evoked potentials
Other: multimodal evoked potentials
All types of Multiple sclerosis patients: * Aged 18 to 58 years old, inclusive, at the time of informed consent. * Expanded Disability Status Scale (EDSS) 0.0 to 6.5. * Have measurable responses on both MEP and SSEP in at least one upper and one lower limb. The MEP and SSEP responses do not need to be in the same limb * Have no comorbid condition (ie neuropathy) that could affect testing. Intervention: multimodal evoked potentials
Other: multimodal evoked potentials
Intraclass correlation coefficient (ICC) of the multi modal evoked potential parameters in order to determine the validity of the compound measures
multi modal evoked potential will include: * MEP latency (msec) * Central motor conduction time (CMCT) using root latency methods (msec) * MEP amplitude (mvolt) and MEP/CMAP amplitude ratio (%)
Time frame: obtained between two assessments done more than 24 hrs but less than 1 month apart
Plan to share: Yes — the data will pooled with 3 other centers to augment the power of the study
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: for the duration of the study and completion of the analyses
Access criteria: all PI's at each center will have access to the data
No publications or documents are linked to this record.
Ran from Apr 2016 to primary completion in Jan 2018, 21 months.
Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's 21 months is below that.
Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clinique Neuro-Outaouais